WallStreetZenWallStreetZen

NASDAQ: TVTX
Travere Therapeutics Inc Stock

Open Broker Account
$19.69-0.52 (-2.57%)
Updated Dec 8, 2022
TVTX Price
$19.69
Fair Value Price
$23.18
Market Cap
$1.26B
52 Week Low
$18.70
52 Week High
$31.65
P/E
-4.71x
P/B
12.55x
P/S
7.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$213.40M
Earnings
-$264.23M
Gross Margin
96.4%
Operating Margin
-117.4%
Profit Margin
-123.8%
Debt to Equity
6.21
Operating Cash Flow
-$159M
Beta
1.03
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

TVTX Overview

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TVTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TVTX ($19.69) is undervalued by 15.04% relative to our estimate of its Fair Value price of $23.18 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
TVTX ($19.69) is not significantly undervalued (15.04%) relative to our estimate of its Fair Value price of $23.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TVTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TVTX due diligence checks available for Premium users.

Be the first to know about important TVTX news, forecast changes, insider trades & much more!

TVTX News

Valuation

TVTX fair value

Fair Value of TVTX stock based on Discounted Cash Flow (DCF)
Price
$19.69
Fair Value
$23.18
Undervalued by
15.04%
TVTX ($19.69) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TVTX ($19.69) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TVTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TVTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.71x
Industry
13.31x
Market
21.39x

TVTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
12.55x
Industry
4.98x
TVTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TVTX's financial health

Profit margin

Revenue
$53.5M
Net Income
-$69.7M
Profit Margin
-130.2%
TVTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TVTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$726.2M
Liabilities
$625.5M
Debt to equity
6.21
TVTX's short-term assets ($534.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TVTX's short-term assets ($534.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TVTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TVTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$39.5M
Investing
$10.1M
Financing
$2.3M
TVTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TVTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
TVTX$1.26B-2.57%-4.71x12.55x
ADPT$1.26B+11.19%-5.63x2.59x
MNKD$1.27B+2.55%-12.68x-5.34x
SNDX$1.27B-3.53%702.33x3.75x
BLU$1.25B+2.27%-19.70x4.21x

Travere Therapeutics Stock FAQ

What is Travere Therapeutics's quote symbol?

NASDAQ: TVTX) Travere Therapeutics trades on the NASDAQ under the ticker symbol TVTX. Travere Therapeutics stock quotes can also be displayed as NASDAQ: TVTX.

If you're new to stock investing, here's how to buy Travere Therapeutics stock.

What is the 52 week high and low for Travere Therapeutics (NASDAQ: TVTX)?

(NASDAQ: TVTX) Travere Therapeutics's 52-week high was $31.65, and its 52-week low was $18.70. It is currently -37.79% from its 52-week high and 5.29% from its 52-week low.

How much is Travere Therapeutics stock worth today?

(NASDAQ: TVTX) Travere Therapeutics currently has 64,173,570 outstanding shares. With Travere Therapeutics stock trading at $19.69 per share, the total value of Travere Therapeutics stock (market capitalization) is $1.26B.

Travere Therapeutics stock was originally listed at a price of $1.50 in Nov 8, 2012. If you had invested in Travere Therapeutics stock at $1.50, your return over the last 10 years would have been 1,212.67%, for an annualized return of 29.36% (not including any dividends or dividend reinvestments).

How much is Travere Therapeutics's stock price per share?

(NASDAQ: TVTX) Travere Therapeutics stock price per share is $19.69 today (as of Dec 8, 2022).

What is Travere Therapeutics's Market Cap?

(NASDAQ: TVTX) Travere Therapeutics's market cap is $1.26B, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Travere Therapeutics's market cap is calculated by multiplying TVTX's current stock price of $19.69 by TVTX's total outstanding shares of 64,173,570.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.